Active substance : montelukast
Form : chewable tablets
Dosage : 5 mg per tablet
Packaging : Box with 28 tablets (2 blisters of 14 chewable tablets)
Target : children from 6 to 14 years
Alukon is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom ‘as-needed’ short acting beta-agonists provide inadequate clinical control of asthma.
Alukon can also be an alternative to low-dose inhaled corticoids in patients with mild persistent asthma with no recent history of severe asthma attacks requiring oral corticoid therapy, and who have demonstrated inability to adhere to inhaled corticoid therapy.
Alukon is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.
Patients from 6 to 14 years of age
One (1) chewable tablet of 5 mg/day , to be taken in the evening.
Prescription drugs. Please contact your doctor.
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.
Dafra Pharma
